Table 1.
Patient characteristics at study entry.
| Characteristics | AHOD, n = 794 n (%) |
TAHOD, n = 2053 n (%) |
P* |
|---|---|---|---|
| Age (years) | |||
| Mean ± SD | 45 (±9.8) | 38.6 (±10) | <0.001 |
|
| |||
| Gender | |||
| Male | 761 (96) | 1,484 (72.2) | <0.001 |
| Female | 30 (3.8) | 567 (27.6) | |
| Transgender*** | 03 (0.4) | 02 (0.1) | |
|
| |||
| HIV exposure category | |||
| Homosexual contact ± IDU | 618 (78.4) | 485 (23.7) | <0.001 |
| IDU ± heterosexual | 25 (3.2) | 45 (2.2) | |
| Heterosexual | 65 (8.2) | 1,341 (65.6) | |
| Other | 80 (10.2) | 174 (8.5) | |
| Missing | 06 (0.7) | 08 (0.4) | |
|
| |||
| HBV coinfection | |||
| Negative | 649 (81.8) | 1,376 (67) | <0.001 |
| Positive | 22 (2.8) | 171 (8.3) | |
| Missing/never tested | 123 (15.5) | 506 (24.6) | |
|
| |||
| HCV coinfection | |||
| Negative | 631 (79.5) | 1,365 (66.5) | <0.001 |
| Positive | 87 (11) | 128 (6.2) | |
| Missing/never tested | 76 (10) | 560 (27.3) | |
|
| |||
| HIV RNA < 500 copies/mL | 326 (41) | 372 (18) | <0.001 |
| Missing | 58 (7.3) | 880 (43) | |
|
| |||
| CD4+ count cells/μL | 360 (219–569) | 161 (50–280) | <0.001** |
| Median (IQR) | |||
| Missing | 58 (7.3) | 264 (12.9) | |
|
| |||
| Cumulative exposure to cART in years | |||
| Median (IQR) | 2 (0–8.2) | 0 (0–0.2) | <0.001** |
| Number ART naive | 320 (40.3) | 1460 (71) | |
|
| |||
| Body mass index (kg/m2) | |||
| Mean (±SD) | 24 (±3.4) | 21 (±3.4) | <0.001 |
| Missing | 528 (66.5) | 1016 (49.5) | |
|
| |||
| Total cholesterol mmol/L | |||
| Mean (±SD) | 5.15 (±1.3) | 4.88 (±1.4) | <0.001 |
|
| |||
| Triglycerides mmol/L | |||
| Mean (±SD) | 2.44 (±2) | 2.40 (±2.3) | 0.678 |
|
| |||
| HDL-C mmol/L | |||
| Mean (±SD) | 1.15 (±0.5) | 1.25 (±0.4) | <0.001 |
*Comparison by t-test for continuous variables and the χ 2 test for noncontinuous variables. **Comparison by Wilcoxon rank-sum test. A: AHOD: Australian HIV Observational Database; T: TAHOD: TREAT Asia HIV Observational Database. cART: combinational antiretroviral therapy; HBV: hepatitis B coinfection; HCV: hepatitis C coinfection; IDU: Intravenous drug user; IQR: interquartile range; SD: standard deviation. ***Transgender participants were classified as males in the multivariable analyses.